Human immunodeficiency virus mutagenesis during antiviral therapy: Impact of drug-resistant reverse transcriptase and nucleoside and nonnucleoside reverse transcriptase inhibitors on human immunodeficiency virus type 1 mutation frequencies

Journal of Virology

Volumn 79, Issue 18, 2005, Pages 12045-12057

  Chen, Renxiang ^a,c,e   Yokoyama, Masaru ^d   Sato, Hironori ^d   Reilly, Cavan ^a,b   Mansky, Louis M ^a,b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^e GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIVIRUS AGENT; EFAVIRENZ; LAMIVUDINE; LUCIFERASE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZALCITABINE;

ARTICLE; CONTROLLED STUDY; DRUG POTENCY; DRUG RESISTANCE; EMBRYO; FRAMESHIFT MUTATION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOTHESIS; MUTAGENESIS; NONHUMAN; PRIORITY JOURNAL; VIRUS GENE; VIRUS MUTATION; VIRUS REPLICATION; VIRUS STRAIN; WILD TYPE;

ANTI-HIV AGENTS; CATALYTIC DOMAIN; CELL LINE; DRUG RESISTANCE, VIRAL; GENES, VIRAL; HIV INFECTIONS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MODELS, GENETIC; MODELS, MOLECULAR; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS;

AE VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 24644460976     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.79.18.12045-12057.2005     Document Type: Article

References (46)

1. Bacheler, L. T., E. D. Anton, P. Kudish, D. Baker, J. Bunville, K. Krakowski, L. Bolling, M. Aujay, X. V. Wang, D. Ellis, M. F. Becker, A. L. Lasut, H. J. George, D. R. Spalding, G. Hollis, and K. Abremske. 2000. Human immunodeficiency virus type 1 mutations selected in patients falling efavirenz combination therapy. Antimicrob. Agents Chemother. 44:2475-2484.
2. Basarapathruni, A., C. M. Bailey, and K. S. Anderson. 2004. Defining a molecular mechanism of synergy between nucleoside and nonnucleoside AIDS drugs. J. Biol. Chem. 279:6221-6224.
3. Bebenek, K., J. Abbotts, J. D. Roberts, S. H. Wilson, and T. A. Kunkel. 1989. Specificity and mechanism of error-prone replication by human immunodeficiency virus-1 reverse transcriptase. J. Biol. Chem. 264:16948-16956.
4. Bebenek, K., J. Abbotts, S. H. Wilson, and T. A. Kunkel. 1993. Error-prone polymerization by HIV-1 reverse transcriptase. Contribution of template-primer misalignment, miscoding, and termination probability to mutational hot spots. J. Biol. Chem. 268:10324-10334.
5. Bebenek, K., J. D. Roberts, and T. A. Kunkel. 1992. The effects of dNTP pool imbalances on frameshift fidelity during DNA replication. J. Biol. Chem. 267:3589-3596.
6. Boyer, P. L., and S. H. Hughes. 2000. Effects of amino acid substitutions at position 115 on the fidelity of human immunodeficiency virus type 1 reverse transcriptase. J. Virol. 74:6494-6500.
7. Burns, D. P., and H. M. Temin. 1994. High rates of frameshift mutations within homo-oligomeric runs during a single cycle of retroviral replication. J. Virol. 68:4196-4203.
8. Esnouf, R., J. Ren, C. Ross, Y. Jones, D. Stammers, and D. Stuart. 1995. Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Struct. Biol. 2:303-308.
9. Essex, M. 1999. Human immunodeficiency viruses in the developing world. Adv. Virus Res. 53:71-88.
10. Harrigan, P. R., M. Salim, D. K. Stammers, B. Wynhoven, Z. L. Brumme, P. McKenna, B. Larder, and S. D. Kemp. 2002. A mutation in the 3′ region of the human immunodeficiency virus type 1 reverse transcriptase (Y318F) associated with nonnucleoside reverase transcriptase inhibitor resistance. J. Virol. 76:6836-6840.
11. Huang, H., R. Chopra, G. L. Verdine, and S. C. Harrison. 1998. Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. Science 282:1669-1675.
12. Huang, W., A. Gamarnik, K. Limoli, C. J. Petropoulos, and J. M. Whitcomb. 2003. Amino acid substitutions at position 190 of human immunodeficiency virus type 1 reverse transcriptase increase susceptibility to delavirdine and impair virus replication. J. Virol. 77:1512-1523.
13. Johnson, S. J., J. S. Taylor, and L. S. Beese. 2003. Processive DNA synthesis observed in a polymerase crystal suggests a mechanism for the prevention of frameshift mutations. Proc. Natl. Acad. Sci. USA 100:3895-3900.
14. Jonckheere, H., E. De Clercq, and J. Anne. 2000. Fidelity analysis of HIV-1 reverse transcriptase mutants with an altered amino-acid sequence at residues Leu74, Olu89, Tyr115, Tyr183 and Met184. Eur. J. Biochem. 267:2658-2665.
15. Kanki, P. J., D. J. Hamel, J. L. Sankale, C. Hsieh, I. Thior, F. Barin, S. A. Woodcock, A. Gueye-Ndiaye, E. Zhang, M. Montano, T. Siby, R. Marlink, I. NDoye, M. E. Essex, and, S. MBoup. 1999. Human immunodeficiency virus type 1 subtypes differ in disease progression. J. Infect. Dis. 179:68-73.
16. Kati, W. M., K. A. Johnson, L. F. Jerva, and K. S. Anderson. 1992. Mechanism and fidelity of HIV reverse transcriptase. J. Biol. Chem. 267:25988-25997.
17. Kimpton, J., and M. Emerman. 1992. Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene. J. Virol. 66:2232-2239.
18. Kohlstaedt, L. A., J. Wang, J. M. Friedman, P. A. Rice, and T. A. Steitz. 1992. Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 256:1783-1790.
19. Kunkel, T. A., and K. Bebenek. 2000. DNA replication fidelity. Annu. Rev. Biochem. 69:497-529.
20. Lacey, S. F., and B. A. Larder. 1994. Novel mutation (V75T) in human immunodeficiency virus type 1 reverse transcriptase confers resistance to 2′,3′-didehydro-2′,3′-dideoxythymidine in cell culture. Antimicrob. Agents Chemother. 38:1428-1432.
21. Li, Y., Y. Kong, S. Korolev, and G. Waksman. 1998. Crystal structures of the Klenow fragment of Thermus aquaticus DNA polymerase I complexed with deoxyribonucleoside triphosphates. Protein Sci. 7:1116-1123.
22. Louwagie, J., W. Janssens, J. Mascola, L. Heyndrickx, P. Hegerich, G. van der Groen, F. E. McCutchan, and D. S. Burke. 1995. Genetic diversity of the envelope glycoprotein from human immunodeficiency virus type 1 isolates of African origin. J. Virol. 69:263-271.
23. Mansky, L. M. 2003. Mutagenic outcome of combined antiviral drug treatment during human immunodeficiency virus type 1 replication. Virology 307:116-121.
24. Mansky, L. M., and L. C. Bernard. 2000. 3′-Azido-3′- deoxythymidine (zidovudine) and AZT-resistant reverse transcriptase can increase the in vivo mutation rate of human immunodeficiency type 1. J. Virol. 74:9532-9539.
25. Mansky, L. M., E. Le Rouzic, S. Benichou, and L. C. Gajary. 2003. Influence of reverse transcriptase variants, drugs, and Vpr on human immunodeficiency virus type 1 mutation frequencies. J. Virol. 77:2071-2080.
26. Mansky, L. M., D. K. Pearl, and L. C. Gajary. 2002. Combination of drugs and drug-resistant reverse transcriptase results in a multiplicative increase of human immunodeficiency virus type 1 mutation frequencies. J. Virol. 76:9253-9259.
27. Mansky, L. M., S. Preveral, L. Selig, R. Benarous, and S. Benichou. 2000. The interaction of Vpr with uracil DNA glycosylase modulates the human immunodeficiency virus type 1 in vivo mutation rate. J. Virol. 74:7039-7047.
28. Mansky, L. M., and H. M. Temin. 1995. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J. Virol. 69:5087-5094.
29. Meyer, P. R., S. E. Matsuura, A. G. So, and W. A. Scott. 1998. Unblocking of chain-terminated primer by HIV-1 reverse transcriptase through a nucleotide-dependent mechanism. Proc. Natl. Acad. Sci. USA 95:13471-13476.
30. Meyer, P. R., S. E. Matsuura, A. A. Tolun, I. Pfeifer, A. G. So, J. W. Mellors, and W. A. Scott. 2002. Effects of specific zidovudine resistance mutations and substrate structure on nucleotide-dependent primer unblocking by human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 46:1540-1545.
31. Pelemans, H., R. M. Esnonf, H. Jonckheere, E. De Clercq, and J. Balzarini. 1998. Mutational analysis of Tyr-318 within the non-nucleoside reverse transcriptase inhibitor binding pocket of human immunodeficiency virus type 1 reverse transcriptase. J. Biol. Chem. 273:34234-34239.
32. Quan, Y., B. G. Brenner, R. G. Marlink, M. Essex, T. Kurimura, and M. A. Wainberg. 2003. Drug resistance profiles of recombinant reverse transcriptases from human immunodeficiency virus type 1 subtypes A/E, B, and C. AIDS Res. Hum. Retroviruses 19:743-753.
33. Ray, A. S., A. Basavapathruni, and K. S. Anderson. 2002. Mechanistic studies to understand the progressive development of resistance in human immunodeficiency virus type 1 reverse transcriptase to abacavir. J. Biol. Chem. 277:40479-40490.
34. Ren, J., R. Esnouf, E. Garman, D. Somers, C. Ross, I. Kirby, J. Keeling, G. Darby, Y. Jones, D. Stuart, and D. Stammers. 1995. High resolution structures of HIV-1 RT from four RT-inhibitor complexes. Struct. Biol. 2:293-302.
35. Rittinger, K., G. Divita, and R. S. Goody. 1995. Human immunodeficiency virus reverse transcriptase substrate-induced conformational changes and the mechanism of inhibition by nonnucleoside inhibitors. Proc. Natl. Acad. Sci. USA 92:8046-8049.
36. Robertson, D. L., J. P. Anderson, J. A. Bradac, J. K. Carr, B. Foley, R. K. Funkbouser, F. Gao, B. H. Hahn, M. L. Kalish, C. Kuiken, G. H. Learn, T. Leitner, F. McCutchan, S. Osmanov, M. Peeters, D. Pieniazek, M. Salminen, P. M. Sharp, S. Wolinsky, and B. Korber. 2000. HIV-1 nomenclature proposal. Science 288:55-56.
37. Sarafianos, S. G., A. D. Clark, Jr., K. Das, S. Tuske, J. J. Birktoft, P. Ilankumaran, A. R. Ramesha, J. M. Sayer, D. M. Jerina, P. L. Boyer, S. H. Hughes, and E. Arnold. 2002. Structures of HIV-1 reverse transcriptase with pre- and post-translocation AZTMP-terminated DNA. EMBO J. 21:6614-6624.
38. Sato, H., Y. Tomita, K. Ebisawa, A. Hachiya, K. Shibamura, T. Shiino, R. Yang, M. Tatsumi, K. Gushi, H. Umeyama, S. Oka, Y. Takebe, and Y. Nagai. 2001. Augmentation of human immunodeficiency virus type 1 subtype E (CRF01_AE) multiple-drug resistance by insertion of a foreign 11-amino-acid fragment into the reverse transcriptase. J. Virol. 75:5604-5613.
39. Shafer, R. W., and D. A. Vuitton. 1999. Highly active antiretroviral therapy (HAART) for the treatment of infection with human immunodeficiency virus type 1. Biomed. Pharmacother. 53:73-86.
40. Smerdon, S. J., J. Jager, J. Wang, L. A. Kohlstaedt, A. J. Chirino, J. M. Friedman, P. A. Rice, and T. A. Steitz. 1994. Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA 91:3911-3915.
41. Spence, R. A., W. M. Kati, K. S. Anderson, and K. A. Johnson. 1995. Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Science 267:988-993.
42. St Clair, M. H., J. L. Martin, G. Tudor-Williams, M. C. Bach, C. L. Vavro, D. M. King, P. Kellam, S. D. Kemp, and B. A. Larder. 1991. Resistance to ddl and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 253:1557-1559.
43. Tantillo, C., J. Ding, A. Jacobo-Molina, R. G. Nanni, P. L. Boyer, S. H. Hughes, R. Pauwels, K. Andries, P. A. Janssen, and E. Arnold. 1994. Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance. J. Mol. Biol. 243:369-387.
44. Temiakov, D., V. Patlan, M. Anikin, W. T. McAllister, S. Yokoyama, and D. G. Vassylyev. 2004. Structural basis for substrate selection by 17 RNA polymerase. Cell 116:381-391.
45. Tisdale, M., T. Alnadaf, and D. Consens. 1997. Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89. Antimicrob. Agents Chemother. 41:1094-1098.
46. Yin, Y. W., and T. A. Steitz. 2004. The structural mechanism of translocation and helicase activity in T7 RNA polymerase. Cell 116:393-404.